What's Happening?
A clinical trial has revealed that relacorilant, a drug originally used to treat Cushing's syndrome, may extend the lives of patients with platinum-resistant ovarian cancer. This form of cancer progresses within six months of starting platinum-based chemotherapy,
which typically results in a survival expectancy of only one year post-diagnosis. The study, published in the Lancet, involved 381 patients who received either usual treatment or relacorilant. Results showed a 35% reduction in the risk of death among those treated with relacorilant, with an average survival extension of four months compared to the control group. Additionally, a separate study found that patients treated with pembrolizumab alongside usual care lived for an average of 17.7 months, compared to 14 months for those receiving usual care alone. Both drugs have been approved by the FDA for treating platinum-resistant ovarian cancer.
Why It's Important?
The findings from these trials offer hope for patients with platinum-resistant ovarian cancer, a condition with limited treatment options and poor prognosis. The potential extension of survival by several months can significantly impact patient quality of life and provide more time for additional treatments or clinical trials. The approval of relacorilant and pembrolizumab by the FDA underscores the importance of repurposing existing drugs to address unmet medical needs. This approach not only accelerates the availability of new treatments but also reduces the costs and time associated with drug development. The success of these trials may encourage further research into repurposing drugs for other resistant forms of cancer, potentially broadening treatment options for patients.
What's Next?
Further testing is required before relacorilant and pembrolizumab can be approved in the UK, as both trials are currently at phase 3. Researchers will continue to monitor the long-term effects and potential side effects of these treatments. The promising results may lead to additional studies exploring the combination of relacorilant with other therapies to enhance efficacy. Healthcare providers and policymakers may need to consider integrating these treatments into standard care protocols for ovarian cancer, potentially influencing insurance coverage and patient access. The ongoing research could also pave the way for similar studies in other types of cancer, expanding the scope of drug repurposing in oncology.
